Ads
related to: pharmacological management multiple sclerosis pdf file full page- Treatment FAQs
See Frequently Asked
Questions. Get The Answers.
- Patient Stories
See What Real Patients
Are Saying About This Treatment.
- Financial Resources
See Financial & Savings Info.
Learn About Savings Options.
- Patient Resources
Download Resources To
Learn More About Treatment.
- Taking RMS Treatment
Watch A Video On How The
Treatment Is Taken.
- Getting Started
Sign Up For More Info On
How To Get Started.
- Treatment FAQs
Search results
Results From The WOW.Com Content Network
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease , MS disrupts the nervous system's ability to transmit signals , resulting in a range of signs and symptoms , including physical, mental , and sometimes psychiatric problems.
Main symptoms of multiple sclerosis Symptoms and findings in multiple sclerosis. Multiple sclerosis can cause a variety of symptoms varying significantly in severity and progression among individuals: changes in sensation (hypoesthesia), muscle weakness, abnormal muscle spasms, or difficulty moving; difficulties with coordination and balance; problems in speech or swallowing (), visual ...
The McDonald criteria are diagnostic criteria for multiple sclerosis (MS). These criteria are named after neurologist W. Ian McDonald who directed an international panel in association with the National Multiple Sclerosis Society (NMSS) of America and recommended revised diagnostic criteria for MS in April 2001.
Multiple sclerosis can be pathologically defined as the presence of distributed glial scars (or sclerosis) in the central nervous system disseminated in time (DIT) and space (DIS). [2] The gold standard for MS diagnosis is pathological correlation, though given its limited availability, other diagnosis methods are normally used. [ 3 ]
Currently the best predictor for clinical multiple sclerosis is the number of T2 lesions visualized by MRI during the CIS, but it has been proposed to complement it with MRI measures of BBB permeability [97] It is normal to evaluate diagnostic criteria against the "time to conversion to definite".
Ads
related to: pharmacological management multiple sclerosis pdf file full page